Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pulmory Embolism - Overview
Pulmory Embolism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Pulmory Embolism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pulmory Embolism - Companies Involved in Therapeutics Development
Acticor Biotech SAS
Chi Resources Emde Biological Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
F. Hoffmann-La Roche Ltd
India Lysis Technologies LLC
Les Laboratoires Servier SAS
Tasly Pharmaceutical Group Co Ltd
Tianjin Pharmaceuticals Group Co Ltd
Valeo Pharma Inc
Verseon Corp
Pulmory Embolism - Drug Profiles
ACT-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Pulmory Embolism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
edoxaban tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Redesca - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pulmory Embolism - Dormant Projects
Pulmory Embolism - Discontinued Products
Pulmory Embolism - Product Development Milestones
Featured News & Press Releases
Nov 14, 2019: Valeo Pharma announces filing of a New Drug Submission for Low Molecular Weight Heparin in Cada
Oct 25, 2017: IU-based drug-discovery startup aims to use notechnology to digest blood clots in lungs
Oct 11, 2017: IU-based drug-discovery startup wins $10,000 in BioCrossroads New Venture Competition
Feb 23, 2017: Daiichi Sankyo Europe Receives CHMP Positive Opinion for Roteas (edoxaban)
Nov 28, 2016: Research to Be Presented at ASH Annual Meeting Shows Verseon’s New Class of Anticoagulants Prevents Thrombosis While Preserving Platelet Function
Nov 09, 2016: Once-Daily Anticoagulant LIXIA (edoxaban) Approved in Cada for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrent Deep-Vein Thrombosis and Pulmory Embolism
Oct 13, 2016: Daiichi Sankyo Announces New Data to be Presented at the ISPOR EU Congress 2016 Alysing the Safety, Efficacy and Cost-effectiveness of LIXIA (edoxaban)
Sep 01, 2016: Lixia applies to tiol Health Insurance
Aug 26, 2015: UK’s NICE recommends once-daily LIXIA (edoxaban) for the treatment and prevention of recurrent deep vein thrombosis and pulmory embolism in adults
Aug 07, 2015: NICE Recommends Once-daily Lixia (Edoxaban) for Preventing Stroke and Systemic Embolism in People with Non-valvular Atrial Fibrillation
Jun 25, 2015: Daiichi Sankyo’s Once-Daily LIXIA (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT and PE
Oct 28, 2014: U.S. FDA Cardiovascular and Rel Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo’s Once-Daily SAVAYSA for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation
Dec 09, 2013: Phase 3 Data Show Daiichi Sankyo’s Once-Daily Edoxaban Lowered Incidence of VTE Recurrence and Clinically Relevant Bleeding Compared to Warfarin in a Large Subgroup of Patients with Cancer
Sep 01, 2013: Daiichi Sankyo’s Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
Oct 25, 2012: Daiichi Sankyo Completes Enrolment In Hokusai-VTE Phase III Study Of Edoxaban For Treatment And Prevention Of Recurrence Of VTE
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Pulmonary Embolism, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development for Pulmonary Embolism, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pulmonary Embolism - Pipeline by Acticor Biotech SAS, H2 2020
Pulmonary Embolism - Pipeline by China Resources Emde Biological Pharmaceutical Co Ltd, H2 2020
Pulmonary Embolism - Pipeline by Daiichi Sankyo Co Ltd, H2 2020
Pulmonary Embolism - Pipeline by F. Hoffmann-La Roche Ltd, H2 2020
Pulmonary Embolism - Pipeline by Indiana Lysis Technologies LLC, H2 2020
Pulmonary Embolism - Pipeline by Les Laboratoires Servier SAS, H2 2020
Pulmonary Embolism - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2020
Pulmonary Embolism - Pipeline by Tianjin Pharmaceuticals Group Co Ltd, H2 2020
Pulmonary Embolism - Pipeline by Valeo Pharma Inc, H2 2020
Pulmonary Embolism - Pipeline by Verseon Corp, H2 2020
Pulmonary Embolism - Dormant Projects, H2 2020
Pulmonary Embolism - Discontinued Products, H2 2020